Noema Pharma, a Basel, Switzerland-based clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, extended its Series B financing closing at $147M with an investment from EQT Life Sciences.
EQT Life Sciences joined the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Led by CEO Ilise Lombardo, Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. It has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025.
The company intends to use the funds to support its four active Phase 2 trials, with key data readouts anticipated in 2025, including additional development activities for
- basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC);
- gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and
- NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.
The Series B extension followed the initial Series B financing of CHF 103M (USD 112M) announced on March 2023, and a CHF 54M (approx. USD 60M) Series A round in December 2020.
FinSMEs
11/12/2024